A detailed history of American Century Companies Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 332,612 shares of SAGE stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
332,612
Previous 316,331 5.15%
Holding current value
$1.82 Million
Previous $3.44 Million 30.19%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.02 - $13.08 $114,292 - $212,955
16,281 Added 5.15%
332,612 $2.4 Million
Q2 2024

Aug 07, 2024

BUY
$10.58 - $17.9 $508,273 - $859,933
48,041 Added 17.91%
316,331 $3.44 Million
Q1 2024

May 14, 2024

BUY
$18.62 - $26.95 $1.74 Million - $2.52 Million
93,547 Added 53.53%
268,290 $5.03 Million
Q4 2023

Feb 13, 2024

BUY
$17.1 - $22.26 $2.99 Million - $3.89 Million
174,743 New
174,743 $3.79 Million
Q3 2023

Nov 13, 2023

SELL
$16.75 - $48.98 $923,310 - $2.7 Million
-55,123 Reduced 24.74%
167,670 $3.45 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $578,490 - $847,313
14,231 Added 6.82%
222,793 $10.5 Million
Q1 2023

May 11, 2023

BUY
$37.27 - $46.57 $82,329 - $102,873
2,209 Added 1.07%
208,562 $8.75 Million
Q4 2022

Feb 13, 2023

BUY
$32.2 - $43.61 $69,391 - $93,979
2,155 Added 1.06%
206,353 $7.87 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $702,800 - $942,074
21,772 Added 11.93%
204,198 $8 Million
Q2 2022

Aug 12, 2022

SELL
$27.52 - $37.99 $3.02 Million - $4.17 Million
-109,660 Reduced 37.54%
182,426 $5.89 Million
Q1 2022

May 11, 2022

SELL
$30.71 - $45.71 $946,789 - $1.41 Million
-30,830 Reduced 9.55%
292,086 $9.67 Million
Q4 2021

Feb 07, 2022

BUY
$37.06 - $47.11 $678,679 - $862,725
18,313 Added 6.01%
322,916 $13.7 Million
Q3 2021

Nov 10, 2021

BUY
$40.26 - $57.37 $605,228 - $862,443
15,033 Added 5.19%
304,603 $13.5 Million
Q2 2021

Aug 05, 2021

SELL
$54.88 - $79.29 $3.47 Million - $5.02 Million
-63,282 Reduced 17.93%
289,570 $16.5 Million
Q1 2021

May 14, 2021

BUY
$70.65 - $96.76 $10.2 Million - $14 Million
144,693 Added 69.51%
352,852 $26.4 Million
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $691,866 - $1.05 Million
-11,845 Reduced 5.38%
208,159 $18 Million
Q3 2020

Nov 13, 2020

BUY
$41.13 - $62.45 $9,830 - $14,925
239 Added 0.11%
220,004 $13.4 Million
Q2 2020

Aug 13, 2020

BUY
$25.95 - $43.15 $3,451 - $5,738
133 Added 0.06%
219,765 $9.14 Million
Q1 2020

May 14, 2020

SELL
$26.15 - $77.24 $17.1 Million - $50.6 Million
-654,850 Reduced 74.88%
219,632 $6.31 Million
Q4 2019

Feb 12, 2020

BUY
$60.18 - $154.77 $9.25 Million - $23.8 Million
153,731 Added 21.33%
874,482 $63.1 Million
Q3 2019

Nov 13, 2019

BUY
$140.29 - $189.96 $28.8 Million - $39 Million
205,435 Added 39.87%
720,751 $101 Million
Q2 2019

Aug 14, 2019

SELL
$157.85 - $183.09 $8.62 Million - $10 Million
-54,614 Reduced 9.58%
515,316 $94.3 Million
Q1 2019

May 14, 2019

BUY
$89.33 - $163.65 $3.56 Million - $6.52 Million
39,835 Added 7.51%
569,930 $0
Q4 2018

Feb 13, 2019

BUY
$81.94 - $139.71 $6.73 Million - $11.5 Million
82,189 Added 18.35%
530,095 $50.8 Million
Q3 2018

Nov 02, 2018

SELL
$138.11 - $169.04 $10.9 Million - $13.4 Million
-79,156 Reduced 15.02%
447,906 $63.3 Million
Q2 2018

Aug 08, 2018

BUY
$140.36 - $175.76 $28.8 Million - $36 Million
204,831 Added 63.57%
527,062 $82.5 Million
Q1 2018

May 03, 2018

BUY
$152.15 - $192.33 $44.6 Million - $56.4 Million
292,995 Added 1002.17%
322,231 $51.9 Million
Q4 2017

Feb 02, 2018

BUY
$60.72 - $167.34 $236,382 - $651,454
3,893 Added 15.36%
29,236 $4.82 Million
Q3 2017

Nov 01, 2017

BUY
$61.4 - $88.52 $1.56 Million - $2.24 Million
25,343
25,343 $1.58 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.